triple negative breast cancer

[Oncogene] Scientists analyzed clonal dynamics in subclonal population mixtures and used DNA barcode technology that revealed selection for distinct clonal populations in different in vitro and in vivo environmental contexts.

[Merck, Inc.] Merck, Inc. announced that the European Commission has approved KEYTRUDA® , in combination with chemotherapy for the first-line treatment of locally recurrent unresectable or metastatic TNBC in adults whose tumors express PD-L1 and who have not received prior chemotherapy.

[Precigen, Inc.] Precigen, Inc. announced that the US FDA has cleared the Investigational New Drug (IND) application to initiate the Phase I/Ib clinical trial of PRGN-3007 in advanced receptor tyrosine kinase-like orphan receptor 1-positive (ROR1+) hematological and solid tumors.

[Cell Death & Disease] The authors used a murine model of orthotopic breast cancer to study the tumor-intrinsic role of cyclin-dependent kinase 8 (CDK8) in TNBC and linked CDK8 to programmed death-ligand 1 expression.

[Nature Cancer] The authors reported the identification of tumoral ring finger protein 2 (RNF2), the core subunit of polycomb repressor complex 1, as a negative regulator of antitumor immunity in various human cancers, including breast cancer.

[Cancer Cell] Investigators demonstrated that high levels of baseline CXCL13+ T cells are linked to the proinflammatory features of macrophages and can predict effective responses to the combination therapy.